Viking Therapeutics, Inc. (VKTX) Stock
Fundamentals
Recent news

Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
VKTX

3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing
VKTX

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
VKTX

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
VKTX
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.97 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
VKTX

3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing
VKTX

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
VKTX

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
VKTX

Here's Why Viking Therapeutics Shares Slumped Today
Here's Why Viking Therapeutics Shares Slumped Today
VKTX

Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
VKTX

VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks
VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks
VKTX

VKTX Stock Slides After-Hours On $400M Stock-And-Notes Raise After Tuesday’s Rally
VKTX Stock Slides After-Hours On $400M Stock-And-Notes Raise After Tuesday’s Rally
VKTX

Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
VKTX

Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
VKTX
About Viking Therapeutics, Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Brian Lian Ph.D. | President, CEO & Director | 1966 |
| Mr. Gregory S. Zante CPA | Chief Financial Officer | 1971 |
| Mr. Michael Morneau | Vice President of Finance & Administration | 1965 |
| Ms. Katherine Mercier | Vice President of Quality & Compliance | — |
| Mr. Kenneth J. Herman M.B.A. | Senior Vice President of Commercial, Marketing & Sales | — |
| Dr. Geoffrey E. Barker Ph.D. | Chief Development Officer | — |
| Mr. Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer | 1970 |
| Dr. Nils U. Olsson Ph.D. | Senior Vice President of Technical Operations | — |
| Dr. Hubert C. Chen M.D., M.P.H. | Chief Medical Officer | 1969 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
3 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.6 | -5.2 | -13.5 | -8.4 | ||||||||
| 2022 | -24.0 | -12.5 | -8.5 | -24.0 | -12.3 | +35.7 | +6.7 | +10.8 | -15.8 | +50.7 | -7.3 | +127.6 |
| 2023 | +2.8 | +25.1 | +46.2 | +21.3 | -0.7 | -26.2 | -6.1 | -2.5 | -23.7 | -9.8 | +27.7 | +43.0 |
| 2024 | +32.1 | +221.7 | -3.8 | +0.1 | -18.5 | -14.9 | +3.0 | +17.3 | +8.4 | +17.0 | -27.4 | -21.9 |
| 2025 | -20.4 | -8.4 | -6.0 | +20.7 | -6.4 | +1.5 | +22.1 | -17.2 | -4.4 | +39.1 | +2.3 | +1.8 |
| 2026 | -18.0 | +13.1 | -2.4 | -5.4 | +9.1 | +24.8 | -15.3 | +0.5 | +5.6 |



